FAQs

NYU Langone Health (NYULH) is collaborating with Deerfield Management Company, an investment firm dedicated to advancing healthcare, to accelerate the translation of research emerging from NYULH.

The collaboration, Amethyst Innovations, is a private company wholly owned by affiliates of Deerfield Management. Its objective is to fund projects that discover novel therapeutics that have the potential to cure life-altering diseases. This collaboration will rely on the novel insights NYULH researchers and clinicians have and will leverage Deerfield's expertise in accelerating state-of-the-art drug development. Deerfield has committed up to $130 million and additional scientific and operational support.

Principal Investigators whose principal employer is NYULH or who have a faculty appointment at NYULH and are therefore subject to NYULH’s institutional policies are eligible to apply.

Interested faculty should reach out to Gaspar Taroncher-Oldenburg at Gaspar.Taroncher-Oldenburg@nyulangone.org for more information on proposal submission.

No. Amethyst Innovations welcomes applications from all therapeutic areas and modalities.